Episode 1 | The Biotech Blueprint

In this episode, host Sonjoy Brahma, VP of Clinical Operations at tranScrip, is joined by Joab Williamson of Faron Pharmaceuticals to explore the operational realities of working within small emerging biotech companies. They discuss the challenges of rare oncology development, how cash runway and clinical milestones shape strategy, and why flexibility, external expertise and careful planning are essential to balanced decision-making. Together, they share practical insights into managing risk, controlling costs and advancing clinical programmes with confidence in a resource-constrained environment.

Christopher Floyd, Executive Medical Director, is joined by Roz Sutton, Regulatory Expert, to explore how regulatory and medical alignment plays a critical role in de-risking drug development. They discuss why regulatory strategy must be shaped early, how medical rationale strengthens regulatory decision-making, and what it takes to execute with confidence in an evolving landscape. 

Rienk Pypstra, tranScrip’s Chief Medical Officer, joins Marc Lemonnier, Chief Executive Officer of Antabio, to discuss the global threat of antimicrobial resistance. They’ll explore why innovation must outpace bacterial evolution, how economic incentives can sustain antibiotic R&D, and why agility, collaboration, resilience and strategic vision are essential to overcoming resistance and driving the future of AMR.

Rob Fox, tranScrip’s Chief Commercial Officer, joins Dr Christopher Floyd, Executive Medical Director, Early Development, to discuss the leap from preclinical to clinical. They’ll explore why it’s critical to weave a compelling translational narrative, design adaptive first-in-human studies, treat regulators as partners, focus on clarity over clutter in data, avoid decision paralysis and build expert teams aligned for success from day one.

Dr Rienk Pypstra, tranScrip’s CMO, joins David Findlay, CEO of Rostra Therapeutics, to lay out the essential blueprint for biotech success. They’ll explore why it’s vital to define a laser-focused vision & mission, build an early Target Product Profile, win investor confidence with a data-driven route to market, engage regulators from day one and select partners who add real value.